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TRANSIENT ANTI-NMDAR ENCEPHALITIS IN A
NEWBORN INFANT DUE TO TRANSPLACENTAL
TRANSMISSION
A 20-year-old woman developed anti–NMDA recep-
tor (NMDAR) encephalitis with psychosis, dysphagia,
hemiparesis, generalized dystonia, cortical blindness,
and status epilepticus. IgG NMDAR antibodies were
present in serum and CSF (figure). She was successfully
treated with IV immunoglobulin (IVIg), plasmaphere-
sis, and carbamazepine. She relapsed 1.5 years later and
was treated regularly with IVIg and carbamazepine
since that time. She became pregnant 2.5 years after
the relapse. There were some remaining cognitive def-
icits, but she had been stable since the relapse. At 37
weeks of gestation a boy was born, weighing 2.5 kg. At
birth, he responded little to manual stimulation and
had respiratory insufficiency. The Moro, rooting,
grasp, sucking, and swallowing reflexes were decreased
or absent but his muscle tone was normal. He did not
respond to venous cannulation. The infant remained
lethargic and required supplemental oxygen and gastric
tube feeding. He received IV antibiotics for 3 days. At
day 6 he opened his eyes for the first time and slowly
started bottle drinking. Because the infant improved
after several days, no lumbar puncture was performed.
By day 10 his feeding problems had resolved.
Because the clinical symptoms of the neonate could
be due to several causes, an extended diagnostic workup
was performed, including liver, kidney, and thyroid
function; infection and coagulation parameters; blood
gas; glucose; ammonia in blood; cytomegalovirus in
urine; and cerebral ultrasound. No abnormalities were
found. The neonatal carbamazepine plasma concentra-
tion was very low (1.1 mg/L). Without any improve-
ment on day 3, we ordered serum NMDAR
antibodies, which returned positive by cell-based assay
(CBA; EuroImmun, Lübeck, Germany), immunohis-
tochemistry, and live hippocampal neurons, confirming
the diagnosis of anti-NMDAR encephalitis (figure).
NMDAR antibodies were no longer detectable by
immunohistochemistry and were weakly positive by
CBA at 3 months and 1 year. At 12 months his devel-
opment was normal.
Anti-NMDAR encephalitis is an autoimmune dis-
order mediated by pathogenic NMDAR antibodies.1 It
can occur at all ages (median age 19) and has been
reported in pregnant women.2–5 Maternal IgG anti-
bodies can cross the placenta and cause diseases in
newborn infants. We report a case of a newborn with
anti-NMDAR encephalitis due to intrauterine transfer
of maternal NMDAR antibodies in a mother without
active clinical symptoms 4 years after her disease.
Maternal antibodies of subtype IgG1 and IgG3 can
cross the placenta from weeks 14–16 of pregnancy and
cause autoimmune newborn diseases.6 It is known that
in many maternal autoimmune diseases, such as Graves
disease, systemic lupus erythematosus, and myasthenia
gravis, the newborn infant remains asymptomatic dur-
ing pregnancy. These women deliver in the hospital to
monitor both mother and child. Only 6 newborn in-
fants from mothers with acute anti-NMDAR enceph-
alitis during pregnancy have been described. Five of
these infants did not have neurologic symptoms.4 In
2 infants antibody tests were performed, which were
negative. In the only symptomatic infant, the mother
developed acute anti-NMDAR encephalitis in the sec-
ond month of pregnancy and remained severely ill in
the intensive care unit.5 She had severely fluctuating
blood pressures and uteroplacental hemodynamics,
leading to uteroplacental insufficiency. She delivered
spontaneously at 34 weeks of gestation and died 2
weeks later due to complications of her illness. The
newborn had neurologic symptoms and transient serum
anti-NMDAR antibodies, and the child had a develop-
mental delay at 3 years of age with cortical dysplasia on
the cerebral MRI. In that report, it is impossible to
distinguish between the effects of maternal illness and
the effect of maternally derived NMDAR antibodies.
The critical period in utero combined with prematurity
could have resulted in the cerebral MRI lesions and the
neurologic sequelae.5
In our case, the mother was in good condition
before, during, and after pregnancy. After the difficult
neonatal period, the infant developed well. To
exclude false-positive results reported in CBAs using
serum testing only, we performed immunohisto-
chemistry showing the characteristic hippocampal
staining and positive live hippocampal neuron stain-
ing. In combination with the clinical presentation,
we diagnosed anti-NMDAR encephalitis.7 Therefore,
we did not perform a lumbar puncture.
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The clinical symptoms related to anti-NMDAR
encephalitis can mimic many neonatal conditions, such
as prematurity, infection, asphyxia, medication-related
side effects, maternal substance abuse, pulmonary dis-
eases, and neurologic diseases. Because anti-NMDAR
encephalitis occurs frequently in adolescents and young
women, risk assessment of pregnancy is necessary.2Most
patients will remain antibody-positive in serum and
CSF after recovery.7 This case illustrates that asymptom-
atic pregnant women with low antibody titers and with-
out any symptoms can deliver symptomatic neonates.
Testing NMDAR antibodies in pregnant women with a
history of anti-NMDAR encephalitis is recommended.
If antibodies are present, we recommend clinical mon-
itoring of the neonate during and after birth.
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Figure Clinical course and CSF/serum NMDA receptor (NMDAR) antibody (ab) titers of mother and infant
Titers were measured with immunohistochemistry of rat brain as described before.7 Broken x-axis represents a change of
units from months to weeks at the birth of the infant. Circles and boxes represent titers (left y-axis), and the shaded areas
represent the clinical course (right y-axis; light gray 5 mother, light green 5 infant) using the modified Rankin Scale (mRS)
(0 5 normal, 1 5 no disability, 2 5 slight disability, 3 5 moderate disability, 4 5 moderately severe disability, 5 5 severe
disability, bedridden, 6 5 dead). CBA 5 cell-based assay.
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